Extended criteria donors in liver transplant candidates with hepatorenal syndrome

Clinical Transplantation

Volumn 25, Issue 3, 2011, Pages

  Briceño, Javier ^a   Ciria, Ruben ^a   de la Mata, Manuel ^a   Montero, José Luis ^a   Rufián, Sebastián ^a   López Cillero, Pedro ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Extended criteria donors; Graft dysfunction; Hepatorenal syndrome; Model of end stage liver disease; Organ allocation

Indexed keywords

CREATININE; SODIUM;

ADULT; AGED; ARTICLE; ASCITES; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; END STAGE LIVER DISEASE; EXTENDED CRITERIA DONOR; FEMALE; GRAFT FAILURE; GRAFT MACROSTEATOSIS; GRAFT RECIPIENT; GRAFT STEATOSIS; GRAFT SURVIVAL; HEMODIALYSIS; HEPATORENAL SYNDROME; HUMAN; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STEATOSIS; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HEPATORENAL SYNDROME; HUMANS; KIDNEY FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TISSUE DONORS; YOUNG ADULT;

EID: 79958717129     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01402.x     Document Type: Article

References (24)

1. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002: 35: 1179.
2. Alessandria C, Ozdogan O, Guevara M et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005: 41: 1282.
3. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008: 8: 419.
4. Munoz SJ. The hepatorenal syndrome. Med Clin North Am 2008: 92: 813.
5. Gonwa TA, Jennings LS, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004: 10: 301.
6. Davis CL. Controversies in combined liver-kidney transplantation: indication and outcomes. Transplant Rev 2008: 22: 82.
7. Foster R, Zimmerman M, Trotter JF. Expanding donor options: marginal, living and split donors. Clin Liver Dis 2007: 11: 417.
8. Barshes NR, Horwitz IB, Franzini L, Vierling JM, Goss JA. Waitlist mortality deceases with increased use of extended criteria donor liver grafts at adult liver transplant centers. Am J Transplant 2007: 7: 1265.
9. Durand F, Renz JF, Alkofer B et al. Report of the Paris consensus meeting on expanded criteria donor in liver transplantation. Liver Transpl 2008: 14: 1694.
10. Briceno J, Marchal T, Padillo J, Solórzano G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation 2002: 74: 522.
11. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003: 9: 651.
12. Silberhumer GR, Pokorny H, Hetz H et al. Combination of extended donor criteria and changes in the Model for End-Stage Liver Disease score predicts patient survival and primary dysfunction in liver transplantation: a retrospective analysis. Transplantation 2007: 83: 588.
13. Fishbein TM, Fiel MI, Emre S et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997: 64: 248.
14. Cheng YF, Chen CL, Lai CY et al. Assessment of donor fatty livers for liver transplantation. Transplantation 2001: 71: 1221.
15. Adinolfi L, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001: 33: 1358.
16. Arroyo V, Gines P, Gerbes A et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996: 23: 164.
17. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type 1 and type 2 hepatorenal syndrome. J Hepatol 2007: 46: 935.
18. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007: 56: 1310.
19. Salerno F, Cazzaniga M, Gobbo G. Pharmacological treatment of hepatorenal síndrome: a note of optimism. J Hepatol 2007: 47: 729.
20. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001: 33: 464.
21. Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002: 36: 202.
22. Briceño J, Ciria R, Pleguezuelo M et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009: 15: 37.
23. De la Mata M, Cuende N, Huet J et al. Model for end-stage liver disease score-based allocation of donors for liver transplantation: a Spanish multicenter experience. Transplantation 2006: 82: 1429.
24. Arroyo V, Terra C, Ginés P. Advances in the pathogenesis and treatment of type 1 and 2 hepatorenal syndrome. J Hepatol 2007: 45: 935.